Findacure and Metabolic Support UK are excited to announce their first joint webinar – What does early access actually mean? – supported by Bionical Emas.
Early access programmes allow patients to access drugs which are not yet fully licenced, but where data suggests could make a transformative difference to their condition.
Known by many names, including compassionate use, these programmes help to provide vital care to patients while the regulatory process is finalised, and have the potential to provide attentional data and real-world insight into the use of new drugs.
In this webinar, Findacure, Metabolic Support UK and Bionical Emas will outline the basic principles of early access schemes, their value to industry and patients, and the role that patient groups can play in ensuring their establishment and success.
